share_log

Analyzing Apyx Medical (NASDAQ:APYX) & EnVVeno Medical (NASDAQ:NVNO)

Analyzing Apyx Medical (NASDAQ:APYX) & EnVVeno Medical (NASDAQ:NVNO)

分析 Apyx Medical(纳斯达克股票代码:APYX)和 Envveno Medical(纳斯达克股票代码:NVNO)
Defense World ·  2023/01/14 01:51

enVVeno Medical (NASDAQ:NVNO – Get Rating) and Apyx Medical (NASDAQ:APYX – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

维诺医疗(纳斯达克:NVNO-GET评级)和阿皮克斯医疗(纳斯达克:APYX-GET评级)都是小盘医疗公司,但哪种投资更好?我们将根据两家公司的风险、股息、收益、盈利能力、估值、分析师推荐和机构持股的强弱对它们进行比较。

Profitability

盈利能力

This table compares enVVeno Medical and Apyx Medical's net margins, return on equity and return on assets.

此表比较了enVVeno Medical和Apyx Medical的净利润率、股本回报率和资产回报率。

Get
到达
enVVeno Medical
EnVVeno医疗
alerts:
警报:
Net Margins Return on Equity Return on Assets
enVVeno Medical N/A -56.38% -53.02%
Apyx Medical -39.28% -39.82% -31.06%
净利润率 股本回报率 资产回报率
EnVVeno医疗 不适用 -56.38% -53.02%
阿皮克斯医疗 -39.28% -39.82% -31.06%

Insider and Institutional Ownership

内部人与机构持股

23.1% of enVVeno Medical shares are owned by institutional investors. Comparatively, 65.6% of Apyx Medical shares are owned by institutional investors. 16.3% of enVVeno Medical shares are owned by insiders. Comparatively, 11.6% of Apyx Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

EnVVeno医疗公司23.1%的股份由机构投资者持有。相比之下,Apyx Medical 65.6%的股份由机构投资者持有。EnVVeno Medical 16.3%的股份由内部人士持有。相比之下,Apyx Medical 11.6%的股份由内部人士持有。强大的机构持股表明,对冲基金、捐赠基金和大型基金管理公司相信,一家公司的长期表现将好于大盘。

Earnings & Valuation

收益与估值

This table compares enVVeno Medical and Apyx Medical's top-line revenue, earnings per share and valuation.
此表比较了enVVeno Medical和Apyx Medical的营收、每股收益和估值。
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
enVVeno Medical N/A N/A -$16.53 million ($2.58) -1.83
Apyx Medical $48.52 million 1.85 -$15.17 million ($0.56) -4.62
总收入 价格/销售额比 净收入 每股收益 市盈率
EnVVeno医疗 不适用 不适用 -1,653万美元 ($2.58) -1.83
阿皮克斯医疗 4,852万美元 1.85 -1,517万元 ($0.56) -4.62

Apyx Medical has higher revenue and earnings than enVVeno Medical. Apyx Medical is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Apyx Medical的收入和收益高于enVVeno Medical。Apyx Medical的市盈率低于enVVeno Medical,表明它目前是两只股票中更负担得起的一只。

Analyst Ratings

分析师评级

This is a breakdown of recent ratings and target prices for enVVeno Medical and Apyx Medical, as provided by MarketBeat.com.

这是由MarketBeat.com提供的enVVeno Medical和Apyx Medical最近的评级和目标价格细目。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
enVVeno Medical 0 0 0 0 N/A
Apyx Medical 0 1 3 0 2.75
销售评级 保持评级 购买评级 强劲的买入评级 评级分数
EnVVeno医疗 0 0 0 0 不适用
阿皮克斯医疗 0 1 3 0 2.75

Apyx Medical has a consensus price target of $6.00, suggesting a potential upside of 131.66%. Given Apyx Medical's higher probable upside, analysts plainly believe Apyx Medical is more favorable than enVVeno Medical.

Apyx Medical的普遍目标价为6美元,暗示潜在上涨131.66%。考虑到Apyx Medical更有可能的上行空间,分析师们显然认为Apyx Medical比enVVeno Medical更有利。

Volatility and Risk

波动性和风险

enVVeno Medical has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

EnVVeno Medical的贝塔系数为1.27,这表明其股价的波动性比标准普尔500指数高27%。相比之下,Apyx Medical的贝塔系数为1.2,这表明其股价的波动性比标准普尔500指数高20%。

Summary

摘要

Apyx Medical beats enVVeno Medical on 8 of the 12 factors compared between the two stocks.

在两只股票比较的12个因素中,Apyx Medical在8个方面击败了enVVeno Medical。

About enVVeno Medical

关于enVVeno医疗公司

(Get Rating)

(获取评级)

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

恩维诺医疗公司(纳斯达克代码:NVNO)是一家医疗设备公司,专注于开发创新的生物假体(基于组织的)设备,以提高静脉疾病治疗的护理标准。该公司的主导产品VenoValve是一种一流的外科植入物,正在开发用于治疗严重的深静脉慢性静脉功能不全(CVI)。当腿部深静脉内的瓣膜受损,导致返回心脏的血液不足时,就会发生深静脉CVI。出现故障的静脉瓣膜导致血液向后流动(回流),并在小腿上积聚,增加腿部静脉内的压力(静脉性高血压)。在最严重的情况下,CVI可导致静脉溃疡(开放性皮肤溃疡),成为慢性且难以治愈。静脉瓣膜被植入股静脉,作为替代静脉瓣膜,旨在减少返流和静脉高血压,并恢复正确的定向血液回流到心脏。据估计,美国约有240万人受到严重的深静脉CVI影响,他们没有有效的治疗选择,VenoValve已获得美国食品和药物管理局指定的突破设备,目前正在SAVVE美国临床试验中进行评估。

About Apyx Medical

关于阿皮克斯医疗公司

(Get Rating)

(获取评级)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Apyx医疗公司是一家能源技术公司,在全球整容和外科市场开发、制造和销售医疗设备。该公司分两个部门运营,先进能源和原始设备制造(OEM)。它提供氦等离子体发生器,用于传输射频能量和氦,以在开放和腹腔镜手术过程中切割、凝固和消融软组织。该公司为整形外科市场提供Renuvion品牌的产品,使整形外科医生、筋膜整形外科医生和整容内科医生能够为组织提供受控的热,以实现他们预期的结果;以及为医院外科市场提供J-等离子品牌的产品。它还开发、制造和销售一次性手机,以及OEM发电机和配件。该公司前身为博维医疗公司,并于2019年1月更名为阿皮克斯医疗公司。阿皮克斯医疗公司成立于1982年,总部设在佛罗里达州克利尔沃特。

Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受enVVeno医学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对enVVeno Medical和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发